Skip to main content

Table 2 Demographic and clinical characteristics of study participants

From: Fibrocyte measurement in peripheral blood correlates with number of cultured mature fibrocytes in vitro and is a potential biomarker for interstitial lung disease in Rheumatoid Arthritis

 

Control

RA

Asthma

IPF/NSIP

RA-ILD

n = 10

n = 10

n = 10

n = 5/n = 4

n = 10

Age, years, median (P25-P75)

56 (51–59)

58 (49–66)

50 (36–56)

75 (66–78)

70 (55–75)

Female sex, n (%)

4 (40)

7 (70)

3 (30)

4 (44)

6 (60)

Current/former/never smokers (%)1

NA

20/10/70

10/20/70

0/78/22

20/70/10

Blood sample results

 

 Hemoglobin, mmol/L, median (P25-P75)

9.1 (8.8–9.5)

7.8 (7.2–8.8)

9.1 (8.7–9.7)

8.5 (7.8–8.9)

8.25 (8–8.5)

 CRP, mg/L, median (P25-P75)

NA

5.4 (2.7–16)

3.2 (1.8–4.7)

2.3 (2–4.4)

8 (1.9–11)

 Leucocytes, 109/L, median (P25-P75)

5.3 (4.6–5.8)

6.8 (5.9–9.6)

8.5 (8.1–9.1)

9.6 (8.2–11)

11.5 (6.7–14.5)

 Monocytes, 109/L, median (P25-P75)

0.5 (0.4–0.6)

0.6 (0.5–0.7)

0.6 (0.5–0.8)

0.8 (0.6–1.1)

0.8 (0.7–1.0)

Radiological signs compatible with interstitial lung disease and/or lung fibrosis2

 

 Chest X-ray (n/N)

0/0

1/7

0/6

9/9

6/10

 High Resolution CT (n/N)

0/0

0/0

0/7

9/9

10/10

Pulmonary Function Test

 

 Lungfunction performed (n/N)

0/0

10/10

10/10 3

9/9

10/10 4

 FVC (% predicted), median (P25-P75)

NA

108 (103–16)

84 (70–99)

78 (66–90)

NA

 TLC (% predicted), median (P25-P75)

NA

99 (94–103)

NA

83 (64–93)

NA

 FEV1 (% predicted), median (P25-P75)

NA

103 (92–112)

71 (61–81)

78 (72–85)

70 (39–86)

 DLCOc (% predicted),median (P25-P75)

NA

79 (67–89) 5

NA

36 (31–37)

58 (46–73)

Asthma patients

 

 GINA score (Average) 6

  

5

  

 ACT score, median (P25-P75)

  

18.5 (16–20)

  

RA patients

 

 Disease Duration (Years), median (P25-P75)

 

5.4 (2.4–17)

  

11.8 (1.4–33)

 DAS28CRP, median (P25-P75)

 

2.75 (1.9–3.8)

  

3.4 (3–4.2)

 Anti-CCP positive (%)/RF positive (%)

 

80/80

  

90/90

 Erosive disease

 

60%

  

90%

 No treatment (%)/DMARDs (%)/Biological treatment (%)

 

10/70/50

  

0/80/50

  1. P25-P75, percentile 25th - percentile 75th; NA = not available; CRP, C-reactive protein; HRCT, High Resolution Computerized Tomography; FVC, Forced Ventilatory Capacity; TLC, Total Lung Capacity; FEV1, Forced Expiratory Volume in 1 s; DLCOc, Diffusion capacity of the Lung for Carbon monoxide corrected for hemoglobin level, GINA, Global Initiative for Asthma; ACT, Asthma Control Test Score; DAS28CRP, Disease Activity Score 28 joints combined with CRP value; CCP, cyclic citrullinated peptide; RF, rheumatoid factor; DMARD, Disease Modifying Anti Rheumatic Drugs. 1) Current or former smokers; 2) More recent than 2 years; 3) Standard Asthma lung-function test without body plethysmography; 4) Most recent lungfunction tests on RA-ILD patients were without FVC and TLC, therefore not stated. 5) One patient without DLCOc value; 6) All patients in anti-IgE treatment